Stockreport

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMER [Read more]